Targeting the Sigma-2 Receptor (S2R) for Dry AMD with an Oral Small Molecule Approach: Preclinical & Clinical Biomarker Support

Time: 1:00 pm
day: Day Two


  • Background on target and rationale for dry AMD
  • Preclinical data support a unique mechanism of action to restore RPE homeostatic function
  • Proteomic biomarker evidence that the S2R modulator CT1812 can alter dry AMD relevant protein and pathways in an aged population